Vestibular Problems Semaglutide and other GLP-1s have been linked to increases in: Vertigo Balance issues Dizziness Inner-ear sensitivity Women with existing vestibular disorders are often more affected and standard dosing is not recommended
CJC-1295 (No DAC), also called Modified GRF(1-29), is a short-acting lab-made analog of growth-hormone-releasing hormone
This predetermined meta-analysis focused on cardiovascular factors and included all seven randomized controlled trials from the tirzepatide T2D clinical development program, known as SURPASS, with a minimum duration of 26 weeks
Ethical considerations Protection of people and animals
Turmeric: Supplements of this spice improved pain and function for people with OAin some cases as much as over-the-counter pain relievers, in a review of 10 studies published in the British Medical Journal
In a head-to-head study of the two agents sponsored by Eli Lilly, makers of tirzepatide, found a 20.2% weight loss with tirzepatide compared to a 13.7% weight loss with semaglutide